<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3006245458
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CIFOGRU 2MG/ML VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CIPROFLOXACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Intravenous infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bag
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        26.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MS Pharma " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MS Pharma 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA02 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Cifogru </strong>contains the active substance ciprofloxacin. Ciprofloxacin is an antibiotic belonging to the fluoroquinolone family. Ciprofloxacin works by killing bacteria that cause infections. It only works with specific strains of bacteria.</p><p><strong>Adults</strong><br />Cifogru is used in adults to treat the following bacterial infections:</p><ul><li>&nbsp;respiratory tract infections</li><li>&nbsp;long lasting or recurring ear or sinus infections</li><li>urinary tract infections</li><li>genital tract infections in men and women</li><li>gastro-intestinal tract infections and intra-abdominal infections</li><li>&nbsp;skin and soft tissue infections</li><li>bone and joint infections</li><li>anthrax inhalation exposure</li></ul><p>Ciprofloxacin may be used in the management of patients with low white blood cell counts (neutropenia) who have a fever that is suspected to be due to a bacterial infection.</p><p><br />If you have a severe infection or one that is caused by more than one type of bacterium, you may be given additional antibiotic treatment in addition to Cifogru.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong><br />Cifogru is used in children and adolescents, under specialist medical supervision, to treat the following bacterial infections:</p><ul><li>&nbsp;lung and bronchial infections in children and adolescents suffering from cystic fibrosis</li><li>complicated urinary tract infections, including infections that have reached the kidneys (pyelonephritis)</li><li>anthrax inhalation exposure</li></ul><p>Cifogru may also be used to treat other specific severe infections in children and adolescents when your doctor considered this necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You must not be given Cifogru:</strong></p><ul><li>&nbsp;if you are allergic to the active substance, to other quinolone drugs or to any of the other ingredients of this medicine (listed in Section 6)</li><li>&nbsp;if you are taking tizanidine (see Section 2: Other medicines and Cifogru)</li></ul><p><strong>Warnings and precautions</strong><br />Talk to your doctor before you are given Cifogru</p><ul><li>&nbsp;If you have ever had kidney problems because your treatment may need to be adjusted.</li><li>&nbsp;If you suffer from epilepsy or other neurological conditions.</li><li>&nbsp;If you have a history of tendon problems during previous treatment with antibiotics such as Cifogru.</li><li>&nbsp;If you are diabetic because you may experience a risk of hypoglycemia with ciprofloxacin.</li><li>&nbsp;If you have myasthenia gravis (a type of muscle weakness) because symptoms can be exacerbated.</li><li>&nbsp;If you have heart problems. Caution should be taken when using Ciprofloxacin, if you were born with or have family history of prolonged QT interval (seen on ECG, electrical recording of the heart), have salt imbalance in the blood (especially low level of potassium or magnesium In the blood), have a very slow heart rhythm (called &lsquo;bradycardia&rsquo;), have a weak heart (heart failure), have a history of heart attack (myocardial infarction), you are female or elderly or you are taking other medicines that result in abnormal ECG changes (see section 2: Other medicines and Cifogru).</li><li>&nbsp;If you or a member of your family is known to have a deficiency in glucose-6-phosphate dehydrogenase (G6PD), since you may experience a risk of anemia with ciprofloxacin.</li></ul><p>For the treatment of some genital tract infections, your doctor can prescribe another antibiotic in addition to ciprofloxacin. If there is no improvement in symptoms after 3 days of treatment, please consult your doctor.</p><p>&nbsp;</p><p><strong>While under treatment with Cifogru</strong><br />Tell your doctor immediately, if any of the following occurs during treatment with Cifogru. Your doctor will decide whether treatment with Cifogru needs to be stopped.<br /> Severe, sudden allergic reaction (an anaphylactic reaction/shock, angioedema). Even with the first dose, there is a rare chance that you may experience a severe allergic reaction with the following symptoms: tightness in the chest, feeling dizzy, and feeling sick or faint, or experience<br />dizziness on standing. If this happens, tell your doctor immediately since the administration of Cifogru will have to be stopped.<br /> Pain and swelling in the joints, and tendinitis may occur occasionally, particularly if you are elderly and are also being treated with corticosteroids. Inflammation and ruptures of tendons may occur even within the first 48 hours of treatment or up to several months after discontinuation of Cifogru therapy. At the first sign of any pain or inflammation stop taking Cifogru, contact your doctor and rest the painful area. Avoid any unnecessary exercise as this might increase the risk of a tendon rupture.<br /> If you suffer from epilepsy or other neurological conditions such as cerebral ischemia or stroke, you may experience side effects associated with the central nervous system. If seizure happens, stop taking Cifogru and contact your doctor immediately.<br /> You may experience symptoms of neuropathy such as pain, burning, tingling, numbness and/or muscle weakness. If this happens, stop taking Cifogru and contact your doctor immediately.<br /> You may experience psychiatric reactions after first administration of ciprofloxacin. If you suffer from depression or psychosis, your symptoms may become worse under treatment with Cifogru. In rare cases, depression or psychosis can progress to thoughts of suicide, suicide attempts, or completed suicide. If this happens, contact your doctor immediately.<br /> Hypoglycemia has been reported most often in diabetic patients, predominantly in elderly population. If this happens, contact your doctor immediately.<br /> Diarrhea may develop while you are on antibiotics, including Cifogru, or even several weeks after you have stopped using them. If it becomes severe or persistent or you notice that your stool contains blood or mucus, stop taking Cifogru and contact your doctor immediately, as this can be life threatening. Do not take medicines that stop or slow down bowel movements.<br /> If your eyesight becomes impaired or if your eyes seem to be otherwise affected, consult an eye specialist immediately.<br /> Your skin becomes more sensitive to sunlight or ultraviolet (UV) light under treatment with Cifogru. Avoid exposure to strong sunlight or artificial UV light such as sunbeds.<br /> Tell the doctor or laboratory staff that you are taking Cifogru if you have to provide a blood or urine sample.<br /> If you suffer from kidney problems, tell the doctor because your dose may need to be adjusted.<br /> Cifogru may cause liver damage. If you notice any symptoms such as loss of appetite, jaundice (yellowing of the skin), dark urine, itching, or tenderness of the stomach, contact your doctor immediately<br /> Cifogru may cause a reduction in the number of white blood cells and your resistance to infection may be decreased. If you experience an infection with symptoms such as fever and serious deterioration of your general condition, or fever with local infection symptoms such as sore throat/pharynx/mouth or urinary problems you should see your doctor immediately. A blood test will be taken to check possible reduction of white blood cells (agranulocytosis). It is important to inform your doctor about your medicine.</p><p>&nbsp;</p><p><strong>Other medicines and Cifogru </strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<br />Do not use Cifogru together with tizanidine, because this may cause side effects such as low blood pressure and sleepiness (see Section 2: You must not be given Cifogru ).<br />The following medicines are known to interact with Cifogru in your body. Using Cifogru together with these medicines can influence the therapeutic effect of these medicines. It can also increase the probability of experiencing side effects.<br />Tell your doctor if you are taking:<br /> Vitamin K antagonists (e.g. warfarin, acenocoumarol, phenprocoumon or fluindione) or other oral anti-coagulants (to thin the blood)<br /> probenecid (for gout)<br /> methotrexate (for certain types of cancer, psoriasis, rheumatoid arthritis)<br /> theophylline (for breathing problems)<br /> tizanidine (for muscle spasticity in multiple sclerosis)<br /> olanzapine (an antipsychotic)<br /> clozapine (an antipsychotic)<br /> ropinirole (for Parkinson&rsquo;s disease)<br /> phenytoin (for epilepsy)<br /> cyclosporine (for skin conditions, rheumatoid arthritis and in organ transplantation)<br /> other medicines that can alter your heart rhythm: medicines that belong to the group of antiarrhythmic (e.g. quinidine, hydroquinidine, disopyramide, amiodarone, sotalol, dofetilide, ibutilide), tricyclic antidepressants, some antimicrobials (that belong to the group of macrolides), some antipsychotics<br /> zolpidem (for sleep disorders)</p><p><strong>Cifogru </strong><strong>may increase the levels of the following medicines in your blood:</strong><br /> pentoxifylline (for circulatory disorders)<br /> caffeine<br /> duloxetine (for depression, diabetic nerve damage or incontinence)<br /> lidocaine (for heart conditions or anaesthetic use)<br /> sildenafil (e.g. for erectile dysfunction)<br /> agomelatine (for depression)</p><p><br /><strong>Cifogru with food and drink</strong><br />Food and drink does not affect your treatment with Cifogru .<br /><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.<br />It is preferable to avoid the use of Cifogru during pregnancy.<br />Do not take Cifogru during breast-feeding because ciprofloxacin is excreted in breast milk and can be harmful for your child.<br /><strong>Driving and using machines</strong><br />Cifogru may make you feel less alert. Some neurological adverse events can occur. Therefore, make sure you know how you react to Cifogru before driving a vehicle or operating machinery. If in doubt, talk to your doctor.<br /><strong>Cifogru </strong><strong>contains sodium</strong><br />Cifogru contains 855mg sodium chloride per 100ml of solution; therefore this medicine may not be suitable for you if you are on a low sodium diet. Check with your doctor if you are unsure about this.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor will explain to you exactly how much Cifogru you will be given as well as how often and for how long. This will depend on the type of infection you have and how bad it is.</p><p>Tell your doctor if you suffer from kidney problems because your dose may need to be adjusted.<br />Treatment usually lasts between 5 and 21 days, but may be longer for severe infections.<br />Your doctor will give you each dose by slow infusion through a vein into your bloodstream. For children, the infusion duration is 60 minutes. In adult patients, infusion time is 60 minutes for 400 mg</p><p>Cifogru and 30 minutes for 200 mg Cifogru . Administering the infusion slowly helps prevent immediate side effects occurring.<br />Remember to drink plenty of fluids while you are taking this medicine.<br />If you stop your course of Cifogru , it is important that you finish the course of treatment even if&nbsp;you begin to feel better after a few days. If you stop using this medicine too soon your infection may not be completely cured and the symptoms of the infection may return or get worse. You might also<br />develop resistance to the antibiotic.<br />If you have any further questions about the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />The following section contains the most serious side effects that you can recognize yourself:</p><p>Stop taking Cifogru and contact your doctor immediately in order to consider another antibiotic treatment if you notice any of the following serious side effects:<br /><strong>Uncommon (may affect up to 1 in 100 people)</strong><br /> Seizure (see Section 2: Warnings and precautions)<br /><strong>Rare (may affect up to 1 in 1,000 people)</strong><br /> Severe, sudden allergic reaction with symptoms such as tightness in the chest, feeling dizzy, sick or faint, or experience dizziness when standing up (anaphylactic shock) (see Section 2: Warnings and precautions)<br /> Tendon rupture, particularly affecting the large tendon at the back of the ankle (Achilles tendon) (see Section 2: Warnings and precautions)<br /><strong>Very rare (may affect up to 1 in 10,000 people)</strong><br /> Severe, sudden allergic reaction with symptoms such as tightness in the chest, feeling dizzy, sick or faint, or experience dizziness when standing up (anaphylactic reaction) (see Section 2: Warnings and precautions)<br /> Muscle weakness, inflammation of the tendons which could lead to rupture of the tendon, particularly affecting the large tendon at the back of the ankle (Achilles tendon) (see Section 2: Warnings and precautions)<br /> A serious life-threatening skin rash, usually in the form of blisters or ulcers in the mouth, throat, nose, eyes and other mucous membranes such as genitals which may progress to widespread blistering or peeling of the skin (Stevens-Johnson syndrome, toxic epidermal necrolysis).<br /><strong>Not known (frequency cannot be estimated from the available data)</strong><br /> Unusual feelings of pain, burning tingling, numbness or muscle weakness in the extremities (neuropathy) (see Section 2: Warnings and precautions)<br /> A drug reaction that causes rash, fever, inflammation of internal organs, hematologic abnormalities and systemic illness (DRESS Drug Reaction with Eosinophilia and Systemic Symptoms, AGEP Acute Generalised Exanthematous Pustulosis).<br /><strong>Other side effects which have been observed during treatment with Cifogru are listed below by how&nbsp;likely they are:<br />Common (may affect up to 1 in 10 people)</strong><br /> nausea, diarrhea, vomiting<br /> joint pain and joint inflammation in children<br /> local reaction at the injection site, rash<br /> temporary increased amounts of substances in the blood (transaminases)</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong><br /> joint pain in adults<br /> fungal superinfections<br /> a high concentration of eosinophils, a type of white blood cell, increased or decreased amounts of a blood clotting factor (thrombocytes)<br /> decreased appetite<br /> hyperactivity, agitation, confusion, disorientation, hallucinations<br /> headache, dizziness, sleeping problems, taste disorders, pins and needles, unusual sensitivity to stimuli of the senses, giddiness<br /> eyesight problems including double vision<br /> loss of hearing<br /> rapid heartbeat (tachycardia)<br /> expansion of the blood vessels (vasodilation), low blood pressure<br /> abdominal pain, digestive problems such as stomach upset (indigestion/heartburn), wind<br /> liver disorders, increased amounts of one substance in the blood (bilirubin), jaundice (cholestatic icterus)<br /> itching, hives<br /> poor kidney function, kidney failure<br /> pains in your muscles and bones, feeling unwell (asthenia), fever, fluid retention<br /> increase in blood alkaline phosphatase (a certain substance in the blood)<br /><strong>Rare (may affect up to 1 in 1,000 people)</strong><br /> muscle pain, inflammation of the joints, increased muscle tone and cramping<br /> inflammation of the bowel (colitis) linked to antibiotic use (can be fatal in very rare cases) (see Section 2: Warnings and precautions)<br /> changes to the blood count (leukopenia, leukocytosis, neutropenia, anemia), a drop in the number of red and white blood cells and platelets (pancytopenia), which may be fatal, bone marrow depression which may also be fatal<br /> allergic reaction, allergic swelling (edema), rapid swelling of the skin and mucous membranes (angioedema) (see Section 2: Warnings and precautions)<br /> increased blood sugar (hyperglycemia)<br /> decreased blood sugar (hypoglycemia) (see Section 2: Warnings and precautions)<br /> anxiety reaction, strange dreams, depression (potentially leading to thoughts of suicide, suicide attempts, or completed suicide), mental disturbances (psychotic reactions potentially leading to thoughts of suicide, suicide attempts, or completed suicide) (see Section 2: Warnings and precautions)<br /> decreased skin sensitivity, tremor, migraine, disorder of sense of smell (olfactory disorders)<br /> tinnitus, impaired hearing<br /> fainting, inflammation of the blood vessel (vasculitis)<br /> shortness of breath including asthmatic symptoms<br /> pancreatitis<br /> hepatitis, death of liver cells (liver necrosis) very rarely leading to life-threatening liver failure (see Section 2: Warnings and precautions)<br /> sensitivity to light (see Section 2: Warnings and precautions), small, pin-point bleeding under the skin (petechiae)<br /> blood or crystals in the urine, urinary tract inflammation<br /> excessive sweating<br /> increased levels of the enzyme amylase<br /><strong>Very rare (may affect up to 1 in 10,000 people)</strong><br /> a special type of reduced red blood cell count (haemolytic anemia); a dangerous drop in a type of white blood cells (agranulocytosis) (see Section 2: Warnings and precautions)<br /> allergic reaction called serum sickness-like reaction (see Section 2: Warnings and precautions)<br /> disturbed coordination, unsteady walk (gait disturbance), pressure on the brain (intracranial pressure and pseudotumor cerebri)<br /> visual color distortions<br /> various skin eruptions or rashes<br /> worsening of the symptoms of myasthenia gravis (see Section 2: Warnings and precautions) Not known (frequency cannot be estimated from the available data)<br /> feeling highly excited (mania) or feeling great optimism and overactivity (hypomania)<br /> abnormal fast heart rhythm, life-threatening irregular heart rhythm, alteration of the heart rhythm (called &lsquo;prolongation of QT interval&rsquo;, seen on ECG, electrical activity of the heart)<br /> influence on blood clotting (in patients treated with Vitamin K antagonists)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not store above 30&deg;C, and protect from light.<br />At cool storage temperatures precipitation may occur, which will re-dissolve at room temperature (15&deg;C &ndash; 25&deg;C).<br />Chemical and physical in-use stability has been demonstrated for 24 hours at room temperature (15&deg;C to 25&deg;C). From a microbiological point of view, unless the method of opening and mixing with coinfusion solutions precludes the risk of microbial contamination, the product should be used<br />immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is ciprofloxacin.<br />Cifogru&reg; 2mg/ml Solution for Infusion: Each 1ml contains Ciprofloxacin 2 mg in pack of 100ml &amp; 200ml Bags.</p><p>The other ingredients are Sodium Chloride, Hydrochloric Acid, Lactic acid 88%, Sodium Hydroxide<br />and Water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Each 1ml contains Ciprofloxacin 2 mg in pack of 100ml & 200ml Bags.
Clear, nearly colorless to slightly yellowish solution
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi</p><p>Riyadh &ndash; kingdom of Saudi Arabia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March2020- SPM190299
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>سيفوجرو يحتوي على مادة تسمى سيبروفلوكساسين. سيبروفلوكساسين هو مضاد حيوي ينتمي إلى عائلة الفلوروكينولون يعمل&nbsp;سيبروفلوكساسين من خلال قتل البكتيريا المسببة العدوى. وهو يعمل فقط على سلالات محددة من البكتيريا</p><p><strong>البالغين</strong><br />:يستخدم سيفوجرو لمعالجة الإصابات البكتيرية التالية لدى البالغين<br />إصابة القصبات الهوائية<br />الإصابة طويلة الأمد أو معاودة الإصابة في الأذن أو الجيوب الأنفية<br />إصابة المجاري البولية<br />إصابة الأعضاء التناسلية عند الرجال والنساء<br />إصابة الجهاز الهضمي<br />إصابة الجلد والأنسجة الرخوة<br />إصابة العظام والمفاصل<br />الإصابة الناتجة عن استنشاق الجمرة الخبيثة<br />سيبروفلوكساسين قد يستخدم لعلاج المرضى الذين يكون لديهم عدد منخفض من خلايا الدم البيضاء مع الإصابة بالحمى التي قد تكون مؤشر على الإصابة البكتيريا<br />إذا كنت تعاني من إصابة بليغة أو بإصابة من بكتيريا متعددة، قد تعطى مضاد حيوي إضافي</p><p><br /><strong>الأطفال والمراهقين</strong><br />سيفوجرو يستخدم تحت مراقبة المختصين الطبيين لمعالجة الإصابات البكتيرية التالية لدى الأطفال والمراهقين<br />التهاب الرئة القصبات الهوائية عند الأطفال والمراهقين الذين يعانون من التليف الكيسي<br />الإصابة المعقدة للمجاري البولية، ومن ضمنها تلك التي تصل إلى الكلية<br />التعرض لجمرة الخبيثة</p><p>سيفوجرو قد يستخدم لمعالجة إصابات خطيرة معينة عند الأطفال والمراهقين عندما يقرر الطبيب الحاجة لذلك</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>:يجب ان لا تأخذ سيفوجرو إذا<br />(كانت لديك حساسية لأدوية الكينولون أو اي مكونات أخرى في هذا الدواء (المدرجة في القسم 6<br />(إذا كنت تأخذ دواء تيزانيدين (انظر القسم 2 -&nbsp;سيفوجرو و الأدوية الأخرى</p><p><strong>التحذيرات والاحتياطات</strong><br />:تحدث إلى الطبيب أو الممرضة قبل تلقي سيفوجرو<br />&nbsp;إذا كانت لديك مشاكل في الكلي أو الكبد لأن العلاج حينها قد يحتاج إلى التعديل<br />إذا كنت تعاني من نوبات صرع أو كان لديك مشاكل عصبية أخرى<br />إذا عانيت من مشاكل في الأربطة خلال علاجك بمضادات حيوية مثل ال سيفوجرو<br />إذا كنت مريض سكري قد يكون لديك نسبة أعلى للإصابة بانخفاض نسبة السكر بالدم عند أخذك لل سيبروفلوكساسين<br />&nbsp;إذا كنت تعاني من مرض وهن العضل الوبيل، لأن الأعراض قد تتفاقم<br />إذا كنت تعاني من مشاكل في القلب<br />إذا كنت تعاني من مشاكل في القلب .يجب توخي الحذر عند استخدام سيبروفلوكساسين ، إذا كنت قد ولدت أو لديك تاريخ<br />التسجيل الكهربائي للقلب) ، ولديك خلل في الأملاح في الدم وخاصة&nbsp;ECG عائلي لفترات طويلة من كيو تي (يلاحظ على<br />مستوى منخفض من البوتاسيوم أو المغنيسيوم في الدم ، أو معدل ضربات القلب بطيئًا جدًا (يطلق عليه &quot;بطء القلب)&nbsp;، أن يكون&nbsp;القلب ضعيفًا (فشل القلب) ، إذا كان عندك تاريخ من النوبات القلبية (احتشاء عضلة القلب) ، إذا كان المريض أنثى أو مسن&nbsp;، أو كنت تتناول أدوية أخرى ينتج عنه تغيرات غير طبيعية في تخطيط (القلب(انظر القسم 2: سيفوجرو والأدوية الأخرى<br />حيث قد تتعرض ، (G6PD) &bull; إذا كنت أو كان أحد أفراد عائلتك يعاني من نقص في نزع الهيدروجين 6 فوسفات الجلوكوز<br />لخطر الإصابة بفقر الدم مع سيبروفلوكساسين<br />لعلاج بعض أنواع التهابات الجهاز التناسلي ، يمكن أن يصف الطبيب مضاد حيوي آخر بالإضافة إلى سيبروفلوكساسين. إذا لم يكن هناك تحسن في الأعراض بعد 3 أيام من العلاج ، يرجى استشارة الطبيب</p><p><br /><strong>خلال العلاج مع سيفوجرو </strong><br />أخبر طبيبك فوراً ، إذا حدث أي مما يلي أثناء العلاج ب سيفوجرو . سيقرر طبيبك ما إذا كان العلاج بحاجة إلى إيقاف مع سيفوجرو</p><p>&nbsp;رد الفعل التحسسي الحاد والمفاجئ تفاعل تأقيمي / صدمة ، وذمة وعائية. حتى مع الجرعة الأولى ، هناك فرصة نادرة لتعرضك لرد فعل تحسسي شديد مع الأعراض التالية: ضيق في الصدر ، الشعور بالدوار ، والشعور بالمرض أو الإغماء&nbsp; أو الشعور بالدوار عند الوقوف. إذا حدث هذا ، أخبر طبيبك على الفور&nbsp;</p><p>يجب أن تتوقع قد&nbsp;يحدث ألم وتورم في المفاصل والتهاب الأوتار في بعض الأحيان ، خاصةً إذا كنت مسنا وتجري معالجته أيضًا ب الكورتيكوستيرويدات .قد يحدث التهاب وتمزق الأوتار حتى خلال ال 48 ساعة الأولى من العلاج أو حتى عدة أشهر بعد التوقف عن علاج سيفوجرو .عند أول إشارة لوجود أي ألم أو التهاب يتوقف عن تناول سيفوجرو ، اتصل بطبيبك وأريح المنطقة&nbsp;المؤلمة .تجنب أي ممارسة غير ضرورية لأن هذا قد يزيد من خطر تمزق الأوتار</p><p><br />إذا كنت تعاني من مرض الصرع أو حالات عصبية أخرى مثل نقص التروية الدماغية أو السكتة الدماغية ، فقد تواجه اثارًا جانبية مرتبطة بالجهاز العصبي المركزي .إذا حدث النوبة ، توقف عن تناول سيفوجرو واتصل بطبيبك على الفور<br />قد تواجه أعراض الاعتلال العصبي مثل الألم والحرق والوخز والخدر و / أو ضعف العضلات .إذا حدث هذا ، توقف عن تناول سيفوجرو واتصل بطبيبك على الفور</p><p><br />قد تواجهك تفاعلات نفسية بعد إعطاء أول سيبروفلوكساسين .إذا كنت تعاني من الاكتئاب أو الذهان ، فقد تزداد الأعراض سوءا تحت علاج سيفوجرو .في حالات نادرة ، يمكن للاكتئاب أو الذهان أن يتطور إلى أفكار الانتحار أو محاولات الانتحار أو الانتحار .إذا حدث هذا ، اتصل بطبيبك على الفور</p><p><br />&nbsp;تم الإبلاغ عن نقص السكر في الدم في معظم الأحيان في مرضى السكري ، ومعظمهم من كبار السن .إذا حدث هذا اتصل بطبيبك على الفور</p><p><br />قد يتطور الإسهال أثناء تناولك المضادات الحيوية ، بما في ذلك سيفوجرو ، أو حتى بعد عدة أسابيع من التوقف عن استخدامها .إذا أصبحت شديدة أو ثابتة أو لاحظت أن البراز يحتوي على دم أو مخاط ، توقف عن تناولسيفوجرو واتصل بطبيبكعلى الفور ، لأن هذا يمكن أن يهدد الحياة .لا تأخذ الأدوية التي توقف أو تبطئ حركة الأمعاء</p><p><br />&nbsp;في حالة ضعف بصرك أو إذا كانت عيناك متأثرتين على نحو آخر ، استشر طبيب العيون على الفور</p><p>تصبح بشرتك أكثر حساسية لأشعة الشمس أو الأشعة فوق البنفسجية تحت العلاج مع سيفوجرو .تجنب التعرض لأشعة الشمس القوية أو الأشعة فوق البنفسجية الاصطناعية مثل كراسي الاستلقاء للتشمس</p><p><br />&nbsp;أخبر الطبيب أو موظفي المختبر بأنك تتناول سيفوجرو إذا كان عليك تقديم عينة من الدم أو البول</p><p><br />&nbsp;إذا كنت تعاني من مشاكل في الكلى ، أخبر الطبيب لأن جرعتك قد تحتاج إلى تعديل<br />&nbsp;</p><p>قد يسبب سيفوجرو تلف الكبد .إذا لاحظت أي أعراض مثل فقدان الشهية أو اليرقان&nbsp; اصفرار الجلد&nbsp;&nbsp;أو البول الداكن أو الحكة أو ألم في المعدة ، اتصل بطبيبك على الفور<br />قد يسبب سيفوجرو انخفاضًا في عدد خلايا الدم البيضاء ويمكن تقليل مقاومتك للعدوى. إذا كنت تعاني من عدوى مع أعراض مثل الحمى والتدهور الخطير في حالتك العامة ، أو الحمى مع أعراض العدوى المحلية مثل التهاب الحلق / البلعوم<br />الفم أو مشاكل في البول ، يجب عليك مراجعة الطبيب على الفور. سيتم إجراء اختبار الدم للتحقق من إمكانية الحد من خلايا<br />الدم البيضاء ندرة المحببات. من المهم إبلاغ طبيبك عن الدواء الخاص بك</p><p><br /><strong>سيفوجرو و الأدوية أخرى</strong><br />أخبر طبيبك أو الصيدلي إذا كنت تأخذ ، أو اتخذت مؤخرا أو قد تأخذ أي أدوية أخرى<br />( لا تستخدم سيفوجرو مع دواء تيزانيدين ، لأن هذا قد يسبب آثارًا جانبية مثل انخفاض ضغط الدم والنعاس ( انظر القسم 2 يجب&nbsp;عدم إعطاؤك سيفوجرو<br />من المعروف أن الأدوية التالية تتفاعل مع سيفوجرو في جسمك .يمكن أن يؤثر استخدام سيفوجرو مع هذه الأدوية على التأثير العلاجي لهذه الأدوية .كما يمكن أن تزيد من احتمال مواجهة آثار جانبية<br /><strong>:أخبر طبيبك إذا كنت تتناول</strong><br />مضادات فيتامين ك على سبيل المثال ، الوارفارين ، أوسينوكومارول ، فينبروكومون أو فلانديون أو غيره من مضادات التخثر الفموية لتجلط الدم<br />دواء بروبنسيد لعلاج النقرس<br />ميثوتريكسات لأنواع معينة من السرطان ، الصدفية ، التهاب المفاصل الروماتويدي<br />الثيوفيلين لمشاكل التنفس<br />تيزانيدين لتشنج العضلات في التصلب المتعدد<br />اولانزبين&nbsp;مضاد للذهان<br />كلوزابين مضاد للذهان<br />&nbsp;روبنيرول لمرض الرعاش<br />الفينيتوين )للصرع<br />السايكلوسبورينلحالات الجلد والتهاب المفاصل الروماتويدي وزرع الأعضاء<br />الأدوية الأخرى التي يمكن أن تغير إيقاع قلبك: الأدوية التي تنتمي إلى مجموعة مضادات اضطراب النظم مثل الكينيدين الهيدروكيندين ، ديسوبيراميد ، الأميودارون ، السوتالول ، دوفتيليد ، الإِيبوتيليد ، مضادات الاكتئاب ثلاثية الحلقات ، بعض مضادات&nbsp;الميكروبات التي تنتمي إلى مجموعة الماكروليدات&nbsp;بعض مضادات الذهان<br />الزولبيديم لاضطرابات النوم<br /><strong>قد يزيد عقار سيفوجرو مستويات الأدوية التالية في دمك</strong><br />البنتوكسيفيلين لاضطرابات الدورة الدموية<br />الكافيين<br />دولوكسيتين للاكتئاب أو تلف الأعصاب السكري أو سلس البول<br />ليدوكائين لحالات القلب أو الاستخدام المخدر<br />سالدانفيل&nbsp;على سبيل المثال لضعف الانتصاب<br />أغوميلاتين للاكتئاب</p><p><br /><strong>سيفوجرو مع الطعام والشراب</strong><br />لا يؤثر الطعام والشراب على علاجك مع سيفوجرو<br /><strong>الحمل والرضاعة الطبيعية</strong><br />إذا كنت حاملاً أو مرضعة&nbsp;،أوتعتقدين أنك قد تكونيين حاملا أو تخططين للحمل، اسأل طبيبك أو الصيدلي للحصول علىالمشورة قبل تناول هذا الدواء<br />من الأفضل تجنب استخدام سيفوجرو أثناء الحمل<br />لا تتناول سيفوجرو أثناء الرضاعة الطبيعية لأنه يتم إفراز سيبروفلوكساسين في حليب الثدي ويمكن أن يكون ضارًا لطفلك<br /><strong>القيادة واستخدام الآلات</strong><br />قد يجعلك سيفوجرو تشعر أنك أقل يقظة. بعض الأحداث السلبية العصبية يمكن أن تحدث. لذلك ، تأكد من أنك تعرف كيف تتفاعل مع سيفوجرو قبل قيادة السيارة أو تشغيل الآلات. إذا كنت في شك ، تحدث مع طبيبك<br /><strong>يحتويسيفوجرو على الصوديوم</strong><br />كلوريد صوديوم لكل 100 مل من المحلول ؛ لذلك قد لا يكون هذا الدواء مناسبًا يحتوي سيفوجرو على 855 ملغم<br />لك إذا كنت تتبع نظامًا غذائيًا منخفض الصوديوم. استشر طبيبك إذا كنت غير متأكد من ذلك</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سوف يشرح لك الطبيب بالضبط كمية سيفوجرو التي ستحصل عليها وكم مرة . هذا يعتمد على نوع العدوى لديك ومدى سوءه</p><p><br />أخبر طبيبك إذا كنت تعاني من مشاكل في الكلى لأن جرعتك قد تحتاج إلى تعديل. يستمر العلاج عادة بين 5 أيام و 21 يومًا ولكنه قد يكون أطول للإصابات الشديدة</p><p>سيعطيك طبيبك كل جرعة عن طريق التسريب البطيء عبر الوريد إلى مجرى الدم. بالنسبة للأطفال ، مدة التسريب هي 60 دقيقة. في المرضى البالغين ، يكون وقت التسريب 60 دقيقة ل 400 مجم من سيفوجرو و 30 دقيقة ل 200 مجم من سيفوجرو . تساعد إدارة التسريب ببطء على منع حدوث آثار جانبية فورية<br />تذكر أن تشرب الكثير من السوائل أثناء تناولك هذا الدواء</p><p><br />إذا قمت بإيقاف دورة سيفوجرو الخاصة بك ، فمن المهم أن تنتهي من مسار العلاج حتى إذا بدأت تشعر بالتحسن بعد بضعة أيام. إذا توقفت عن استخدام هذا الدواء في وقت مبكر ، قد يحدث العدوى لا يمكن علاجه تمامًا وقد تعود أعراض الإصابة أو تزداد سوءًا. يمكنك أيضا تطوير مقاومة للمضاد الحيوي</p><p>&nbsp;</p><p>إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية ، يمكن أن يسبب هذا الدواء آثارًا جانبية ، على الرغم من عدم حصول الجميع عليها. يحتوي القسم التالي على الآثار الجانبية الأكثر خطورة التي يمكنك التعرف عليها بنفسك</p><p>:التوقف عن تناول سيفوجرو والاتصال بطبيبك على الفور للنظر في علاج مضاد حيوي آخر إذا لاحظت أيًا من الأعراض الجانبية الخطيرة التالية</p><p><strong><strong>غير شائع قد يؤثر على شخص واحد من بين كل 100 شخص</strong></strong></p><p>(التشنجات (انظر القسم 2: التحذيرات والاحتياطات</p><p><strong><strong>نادر قد يؤثر على 1 من كل 1000 شخص</strong></strong></p><p>تفاعل حساسي حاد ومفاجئ مع أعراض مثل ضيق في الصدر أو الشعور بالدوار أو المرض أو الإغماء أو الشعور بالدوار</p><p>(عند الوقوفصدمة تحسسية (انظر القسم 2: التحذيرات والاحتياطات</p><p>(تمزق الوتر ، الذي يؤثر بشكل خاص على الوتر الكبير في مؤخرة الكاحل وتر العرقوب (انظر القسم 2: التحذيرات والاحتياطات</p><p><strong><strong>نادر جدًا قد يؤثر على شخص واحد من بين كل 10000 شخص</strong></strong></p><p>تفاعل حساسي حاد ومفاجئ مع أعراض مثل ضيق في الصدر أو الشعور بالدوار أو المرض أو الإغماء أو الشعور بالدوار</p><p>(عند الوقوف&nbsp; تفاعل تحسسي (انظر القسم 2: التحذيرات والاحتياطات</p><p>ضعف العضلات ، التهاب الأوتار التي يمكن أن تؤدي إلى تمزق الأوتار ، خاصةً التي تؤثر على الوتر الكبير في الجزء الخلفي من الكاحل وتر العرقوب (انظر القسم 2: (التحذيرات والاحتياطات</p><p>&nbsp;طفح جلدي خطير يهدد الحياة ، وعادة ما يكون في شكل بثور أو قروح في الفم والحلق والأنف والعينين والأغشية المخاطية الأخرى مثل الأعضاء التناسلية التي قد تتطور إلى تقرحات شديدة أو تقشير الجلد )متلازمة ستيفنز جونسون ، انحلال البشرة السمي&nbsp;</p><p><strong><strong>غير معروف لا يمكن تقدير التردد من البيانات المتاحة</strong></strong></p><p>(شعور غير عادي بالألم ، حرق الوخز ، الخدر أو ضعف العضلات في الأطراف اعتلال الأعصاب (انظر القسم 2 التحذيرات والاحتياطات</p><p>رد فعل دوائي يسبب الطفح الجلدي والحمى والتهاب الأعضاء الداخلية والشذوذات الدموية ومرض الجهاز التنفسي تفاعل</p><p>الحاد العملاق البثور.( ASEP ، رد فعل الدواء مع فرط الحمضات والأعراض الجهازية</p><p>&nbsp;</p><p><strong>الآثار الجانبية الأخرى التي لوحظت أثناء العلاج مع </strong>سيفوجرو <strong> مذكورة أدناه حسب مدى احتمال حدوثها</strong></p><p><strong><strong>عام قد يؤثر على شخص واحد من كل 10 أشخاص</strong></strong></p><p>الغثيان والإسهال والقيء</p><p>آلام المفاصل والتهاب المفاصل عند الأطفال</p><p>رد الفعل المحلي في موقع الحقن ، والطفح الجلدي</p><p>زيادة كميات مؤقتة من المواد في الدم&nbsp; الترانسينيراز</p><p><strong><strong>غير شائع قد يؤثر على شخص واحد من بين كل 100 شخص</strong></strong></p><p>آلام المفاصل لدى البالغين</p><p>اإصابة فطرية بسبب الإصابة البكتيرية</p><p>تركيز عالٍ من الحمضيات، وهو نوع من خلايا الدم البيضاء ، زيادة أو نقصان كميات من عامل تخثر الدم )الصفيحات</p><p>قلة الشهية</p><p>فرط النشاط ، والإثارة ، والارتباك ، والارتباك ، والهلوسة صداع&nbsp;، دوار ، مشاكل في النوم ، اضطرابات طعم ، دبابيس وإبر ، حساسية غير عادية لمحفزات الحواس ، الدوخة</p><p>مشاكل البصر بما في ذلك الرؤية المزدوجة</p><p>فقدان السمع</p><p>&nbsp;ضربات القلب السريعة عدم انتظام دقات القلب</p><p>توسع الأوعية الدموية توسع الأوعية&nbsp;وانخفاض ضغط الدم</p><p>ألم في البطن ، ومشاكل في الجهاز الهضمي مثل اضطراب في المعدة )عسر الهضم / حرقان&nbsp;، إنتفاخات</p><p>&bull;اضطرابات الكبد ، كميات متزايدة من مادة واحدة في الدم البيليروبين، واليرقان&nbsp;الركاغي الركودي</p><p>الحكة ، وخلايا النحل</p><p>ضعف وظائف الكلى والفشل الكلوي</p><p>آلام في عضلاتك وعظامك ، والشعور بتوعك )الوهن ، والحمى ، واحتباس السوائل</p><p>- زيادة في فوسفاتاز القلوية الدم - مادة معينة في الدم</p><p><strong><strong>نادر قد يؤثر على 1 من كل 1000 شخص</strong></strong></p><p>ألم العضلات ، التهاب المفاصل ، زيادة قوة العضلات والتقلصات</p><p>(التهاب الأمعاء التهاب القولون&nbsp; المرتبط باستخدام المضادات الحيوية يمكن أن يكون قاتلاً في حالات نادرة جداً (انظر القسم 2: التحذيرات والاحتياطات</p><p>تغيرات في عدد كريات الدم&nbsp;البيضاء،زيادة كريات الدم&nbsp;البيضاء ، قلة العدلات ، فقر الدم( ، انخفاض في عدد خلايا الدمالحمراء والبيضاء والصفائح الدموية )قلة الكريات الشاملة( ، والتي قد تكون مميتة ، والاكتئاب العظمي الذي قد يكون مميتًا</p><p>أيضًا</p><p>(رد فعل تحسسي ، تورم أرجي وذمة ، تورم سريع في الجلد والأغشية المخاطية وذمة وعائية (انظر القسم 2 اتحذيرات والاحتياطات</p><p>زيادة نسبة السكر في الدم فرط سكر الدم</p><p>(انخفاض سكر الدم نقص السكر في الدم (انظر القسم 2: التحذيرات والاحتياطات</p><p>ردة فعل القلق ، والأحلام الغريبة ، والاكتئاب&nbsp;مما قد يؤدي إلى أفكار الانتحار ، أو محاولات الانتحار ، أو الانتحار المكتمل&nbsp;(انظر القسم 2: التحذيرات و الاحتياطات</p><p>انخفاض حساسية الجلد ، ورعاش ، والصداع النصفي ، واضطراب في حاسة الشم )اضطرابات شمية</p><p>الطنين ، ضعف السمع الإغماء ، التهاب الأوعية الدموية&nbsp;</p><p>ضيق التنفس بما في ذلك أعراض الربو</p><p>التهاب البنكرياس</p><p>(التهاب الكبد ، موت خلايا الكبد نخر الكبد&nbsp;نادراً ما يؤدي إلى فشل كبد يهدد الحياة (انظر القسم 2: التحذيرات والاحتياطات</p><p>حساسية للضوء (انظر القسم 2: التحذيرات والاحتياطات) ، نزيف صغير ، نقطة طرفية تحت الجلد نمشات</p><p>الدم أو البلورات في البول ، التهاب المسالك البولية</p><p>التعرق المفرط</p><p>&nbsp;زيادة مستويات إنزيم الأميليز</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ابق هذا الدواء بعيدا عن متناول الأطفال</p><p>لا تقم بتخزين ما يزيد على 30 درجة مئوية ، وحماية من الضوء</p><p>في درجات حرارة التخزين البارد قد يحدث ترسيب &nbsp;، والتي سيعاد إذابته في درجةحرارة الغرفة (15-25 درجة مئوية)</p><p>تم إثبات استقرار كيميائي وفيزيائي أثناء الاستخدام لمدة 24 ساعة في درجة حرارة الغرفة ) 15 درجة مئوية إلى 25 درجة مئوية. من وجهة نظر ميكروبيولوجية ، ما لم تستبعد طريقة الفتح والمزج مع حلول التشريب خطر التلوث الجرثومي</p><p>يجب استخدام المنتج على الفور. إذا لم يتم استخدامها على الفور ، فإن أوقات وشروط التخزين أثناء الاستخدام تقع على عاتق المستخدم</p><p>لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية</p><p>اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. هذه التدابير سوف تساعد في حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي سيبروفلوكساسين<br />&nbsp;&nbsp; سيفوجرو محلول للحقن الوريدي بالتسريب: يحتوي كل 1 مل على 2 ملغم&nbsp;سيبروفلوكساسين في&nbsp;تعبئة 100 مل و 200 مل</p><p>المكونات الأخرى هي كلوريد الصوديوم ، حمض الهيدروكلوريك ، حمض اللاكتيك 88 ٪ ، هيدروكسيد الصوديوم والماء<br />للحقن</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            يحتوي كل 1 مل على 2 ملغم سيبروفلوكساسين في تعبئة 100 مل و 200 مل
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>ام اس فارما &ndash; السعودية</p><p>الرياض - المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مار س - 2020 SPM190299
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cifogru Solution for intravenous infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bag 100ml contains 200 mg of Ciprofloxacin as active substance.
Bag 200ml contains 400 mg of Ciprofloxacin as active substance.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for intravenous infusion.
Clear, nearly colorless to slightly yellowish solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cifogru solution for infusion is indicated for the treatment of the following infections (see sections 4.4 and 5.1). Special attention should be paid to available information on resistance to ciprofloxacin before commencing therapy.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p><p>Adults</p><p>&bull; Lower respiratory tract infections due to Gram-negative bacteria</p><p>- Exacerbations of chronic obstructive pulmonary disease</p><p>- Broncho-pulmonary infections in cystic fibrosis or in bronchiectasis</p><p>- Pneumonia</p><p>&bull; Chronic suppurative otitis media</p><p>&bull; Acute exacerbation of chronic sinusitis especially if these are caused by Gram-negative bacteria</p><p>&bull; Urinary tract infections</p><p>&bull; Genital tract infections</p><p>- Epididymo-orchitis including cases due to susceptible <em>Neisseria gonorrhoeae</em></p><p>- Pelvic inflammatory disease including cases due to susceptible <em>Neisseria gonorrhoeae</em></p><p>&bull; Infections of the gastro-intestinal tract (e.g. travelers&rsquo; diarrhea)</p><p>&bull; Intra-abdominal infections</p><p>&bull; Infections of the skin and soft tissue caused by Gram-negative bacteria</p><p>&bull; Malignant external otitis</p><p>&bull; Infections of the bones and joints</p><p>&bull; Inhalation anthrax (post-exposure prophylaxis and curative treatment)</p><p>Ciprofloxacin may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.</p><p>Children and adolescents</p><p>&bull; Broncho-pulmonary infections in cystic fibrosis caused by <em>Pseudomonas aeruginosa</em></p><p>&bull; Complicated urinary tract infections and pyelonephritis</p><p>&bull; Inhalation anthrax (post-exposure prophylaxis and curative treatment)</p><p>Ciprofloxacin may also be used to treat severe infections in children and adolescents when this is considered necessary.</p><p>Treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents (see sections 4.4 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p>The dosage is determined by the indication, the severity and the site of the infection, the susceptibility to ciprofloxacin of the causative organism(s), the renal function of the patient and, in children and adolescents the body weight.</p><p>The duration of treatment depends on the severity of the illness and on the clinical and bacteriological course.</p><p>After intravenous initiation of treatment, the treatment can be switched to oral treatment with tablet or suspension if clinically indicated at the discretion of the physician. IV treatment should be followed by oral route as soon as possible.</p><p>In severe cases or if the patient is unable to take tablets (e.g. patients on enteral nutrition), it is recommended</p><p>to commence therapy with intravenous ciprofloxacin until a switch to oral administration is possible.</p><p>Treatment of infections due to certain bacteria (e.g. <em>Pseudomonas aeruginosa</em>, <em>Acinetobacter </em>or <em>Staphylococci</em>)</p><p>may require higher ciprofloxacin doses and co-administration with other appropriate antibacterial agents.</p><p>Treatment of some infections (e.g. pelvic inflammatory disease, intra-abdominal infections, infections in neutropenic patients and infections of bones and joints) may require co-administration with other appropriate antibacterial agents depending on the pathogens involved.</p><p>&nbsp;</p><p>Adult</p><p>((Table))</p><p>&nbsp;</p><p>pediatric population&nbsp;</p><p>((Table))</p><p>&nbsp;</p><p><em><u>Elderly patients</u></em></p><p>Elderly patients should receive a dose selected according to the severity of the infection and the patient`s creatinine clearance.</p><p><em><u>Patients with renal and hepatic impairment</u></em></p><p>Recommended starting and maintenance doses for patients with impaired renal function:</p><p>((Table))</p><p>&nbsp;</p><p>In patients with impaired liver function, no dose adjustment is required.</p><p>Dosing in children with impaired renal and/or hepatic function has not been studied.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Cifogru solution for infusion should be checked visually prior to use. It must not be used if cloudy.</p><p>Ciprofloxacin should be administered by intravenous infusion. For children, the infusion duration is 60 minutes.</p><p>In adult patients, infusion time is 60 minutes for 400 mg Cifogru solution for infusion and 30 minutes for 200 mg Cifogru solution for infusion. Slow infusion into a large vein will minimize patient discomfort and reduce the risk of venous irritation.</p><p>The infusion solution can be infused either directly or after mixing with other compatible infusion solutions (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance, to other quinolones or to any of the excipients listed in section 6.1.
• Concomitant administration of ciprofloxacin and tizanidine (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Severe infections and mixed infections with Gram‐positive and anaerobic pathogens</u></p><p>Ciprofloxacin monotherapy is not suited for treatment of severe infections and infections that might be due to Gram‐positive or anaerobic pathogens. In such infections, ciprofloxacin must be co‐administered with other appropriate antibacterial agents.</p><p><u>Streptococcal Infections (including Streptococcus pneumonia)</u></p><p>Ciprofloxacin is not recommended for the treatment of streptococcal infections due to inadequate efficacy.</p><p><u>Genital tract infections</u></p><p>Epididymo‐orchitis and pelvic inflammatory diseases may be caused by fluoroquinolone‐resistant</p><p><em>Neisseria gonorrhoeae </em>isolates.</p><p>For epididymo‐orchitis and pelvic inflammatory diseases, empirical ciprofloxacin should only be considered in combination with another appropriate antibacterial agent (e.g. a cephalosporin) unless ciprofloxacin‐resistant <em>Neisseria gonorrhoeae </em>can be excluded. If clinical improvement is not achieved after 3 days of treatment, the therapy should be reconsidered.</p><p><u>Urinary tract infections</u></p><p>Resistance to fluoroquinolones of <em>Escherichia coli </em>&ndash; the most common pathogen involved in urinary tract infections &ndash; varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in <em>Escherichia coli </em>to fluoroquinolones.</p><p><u>Intra‐abdominal infections</u></p><p>There are limited data on the efficacy of ciprofloxacin in the treatment of post‐surgical intra‐abdominal infections.</p><p><u>Travellers&#39; diarrhea</u></p><p>The choice of ciprofloxacin should take into account information on resistance to ciprofloxacin in relevant pathogens in the countries visited.</p><p><u>Infections of the bones and joints</u></p><p>Ciprofloxacin should be used in combination with other antimicrobial agents depending on the results of the microbiological documentation.</p><p><u>Inhalational anthrax</u></p><p>Use in humans is based on <em>in‐vitro </em>susceptibility data and on animal experimental data together with limited human data. Treating physicians should refer to national and /or international consensus documents regarding the treatment of anthrax.</p><p><u>Pediatric population</u></p><p>The use of ciprofloxacin in children and adolescents should follow available official guidance.</p><p>Ciprofloxacin treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents.</p><p>Ciprofloxacin has been shown to cause arthropathy in weight‐bearing joints of immature animals. Safety data from a randomized double‐blind study on ciprofloxacin use in children (ciprofloxacin: n=335, mean age = 6.3 years; comparators: n=349, mean age = 6.2 years; age range = 1 to 17 years) revealed an incidence of suspected drug‐related arthropathy (discerned from joint‐related clinical signs and symptoms) by Day +42 of 7.2% and 4.6%. Respectively, an incidence of drug‐related arthropathy by 1‐ year follow‐up was 9.0% and 5.7%. The increase of suspected drug‐related arthropathy cases over time was not statistically significant between groups. Treatment should be initiated only after a careful benefit/risk evaluation, due to possible adverse events related to joints and/or surrounding tissue (see section 4.8).</p><p><em><u>Broncho‐pulmonary infections in cystic fibrosis</u></em></p><p>Clinical trials have included children and adolescents aged 5‐17 years. More limited experience is available in treating children between 1 and 5 years of age.</p><p><em>Complicated urinary tract infections and pyelonephritis</em></p><p>Ciprofloxacin treatment of urinary tract infections should be considered when other treatments cannot be used, and should be based on the results of the microbiological documentation.</p><p>Clinical trials have included children and adolescents aged 1‐17 years.</p><p><em>Other specific severe infections</em></p><p>Other severe infections in accordance with official guidance, or after careful benefit‐risk evaluation when other treatments cannot be used, or after failure to conventional therapy and when the microbiological documentation can justify a ciprofloxacin use.</p><p>The use of ciprofloxacin for specific severe infections other than those mentioned above has not been evaluated in clinical trials and the clinical experience is limited. Consequently, caution is advised when treating patients with these infections.</p><p><u>Hypersensitivity</u></p><p>Hypersensitivity and allergic reactions, including anaphylaxis and anaphylactic reactions, may occur following a single dose (see section 4.8) and may be life‐threatening. If such reaction occurs, ciprofloxacin should be discontinued and an adequate medical treatment is required.</p><p>&nbsp;</p><p><u>Musculoskeletal System</u></p><p>Ciprofloxacin should generally not be used in patients with a history of tendon disease/disorder related to quinolone treatment. Nevertheless, in very rare instances, after microbiological documentation of the causative organism and evaluation of the risk/benefit balance, ciprofloxacin may be prescribed to these patients for the treatment of certain severe infections, particularly in the event of failure of the standard therapy or bacterial resistance, where the microbiological data may justify the use of ciprofloxacin.</p><p>Tendinitis and tendon rupture (especially Achilles tendon), sometimes bilateral, may occur with ciprofloxacin, even within the first 48 hours of treatment. Inflammation and ruptures of tendon may occur even up to several months after discontinuation of ciprofloxacin therapy. The risk of tendinopathy may be increased in elderly patients or in patients concomitantly treated with corticosteroids (see section 4.8).</p><p>At any sign of tendinitis (e.g. painful swelling, inflammation), ciprofloxacin treatment should be discontinued. Care should be taken to keep the affected limb at rest.</p><p>Ciprofloxacin should be used with caution in patients with myasthenia gravis, because symptoms can be exacerbated (see section 4.8).</p><p><u>Vision disorders</u></p><p>If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately.</p><p><u>Photosensitivity</u></p><p>Ciprofloxacin has been shown to cause photosensitivity reactions. Patients taking ciprofloxacin should be advised to avoid direct exposure to either extensive sunlight or UV irradiation during treatment (see section 4.8).</p><p><u>Central Nervous System</u></p><p>Ciprofloxacin like other quinolones are known to trigger seizures or lower the seizure threshold. Cases of status epilepticus have been reported. Ciprofloxacin should be used with caution in patients with CNS disorders which may be predisposed to seizure. If seizures occur, ciprofloxacin should be discontinued (see section 4.8). Psychiatric reactions may occur even after first administration of ciprofloxacin. In rare cases, depression or psychosis can progress to suicidal ideations/thoughts culminating in attempted suicide or completed suicide. In the occurrence of such cases, ciprofloxacin should be discontinued. Cases of polyneuropathy (based on neurological symptoms such as pain, burning, sensory disturbances or muscle weakness, alone or in combination) have been reported in patients receiving ciprofloxacin.</p><p>Ciprofloxacin should be discontinued in patients experiencing symptoms of neuropathy, including pain; burning, tingling, numbness, and/or weakness in order to prevent the development of an irreversible condition (see section 4.8).</p><p><u>Cardiac disorders</u></p><p>Caution should be taken when using fluoroquinolones, including ciprofloxacin, in patients with known risk factors for prolongation of the QT interval such as, for example:</p><p>‐ Congenital long QT syndrome</p><p>‐ Concomitant use of drugs that are known to prolong the QT interval (e.g. Class IA and III antiarrhythmic, tricyclic antidepressants, macrolides, antipsychotics)</p><p>‐ Uncorrected electrolyte imbalance (e.g. hypokalemia, hypomagnesaemia)</p><p>‐ Cardiac disease (e.g. heart failure, myocardial infarction, bradycardia) Elderly patients and women may be more sensitive to QTc‐prolonging medications. Therefore, caution should be taken when using fluoroquinolones, including ciprofloxacin, in these populations.</p><p>(See section 4.2 Elderly patients, section 4.5, section 4.8, section 4.9).</p><p><u>Hypoglycemia</u></p><p>As with other quinolones, hypoglycemia has been reported most often in diabetic patients, predominantly in the elderly population. In all diabetic patients, careful monitoring of blood glucose is recommended (see section 4.8).</p><p><u>Gastrointestinal System</u></p><p>The occurrence of severe and persistent diarrhea during or after treatment (including several weeks after treatment) may indicate an antibiotic‐associated colitis (life threatening with possible fatal outcome), requiring immediate treatment (see section 4.8). In such cases, ciprofloxacin should immediately be discontinued, and an appropriate therapy initiated. Anti‐peristaltic drugs are contraindicated in this situation.</p><p><u>Renal and urinary system</u></p><p>Crystal Luria related to the use of ciprofloxacin has been reported (see section 4.8). Patients receiving ciprofloxacin should be well hydrated and excessive alkalinity of the urine should be avoided.</p><p><u>Impaired renal function</u></p><p>Since ciprofloxacin is largely excreted unchanged via renal pathway dose adjustment is needed in patients with impaired renal function as described in section 4.2 to avoid an increase in adverse drug reactions due to accumulation of ciprofloxacin.</p><p><u>Hepatobiliary system</u></p><p>Cases of hepatic necrosis and life‐threatening hepatic failure have been reported with ciprofloxacin (see section 4.8). In the event of any signs and symptoms of hepatic disease (such as anorexia, jaundice, dark urine, pruritus, or tender abdomen), treatment should be discontinued.</p><p><u>Glucose‐6‐phosphate dehydrogenase deficiency</u></p><p>Hemolytic reactions have been reported with ciprofloxacin in patients with glucose‐6‐phosphate dehydrogenase deficiency. Ciprofloxacin should be avoided in these patients unless the potential benefit is considered to outweigh the possible risk. In this case, potential occurrence of hemolysis should be monitored.</p><p><u>Resistance</u></p><p>During or following a course of treatment with ciprofloxacin bacteria that demonstrate resistance to ciprofloxacin may be isolated, with or without a clinically apparent superinfection. There may be a particular risk of selecting for ciprofloxacin‐resistant bacteria during extended durations of treatment and when treating nosocomial infections and/or infections caused by <em>Staphylococcus </em>and <em>Pseudomonas</em></p><p><em>species</em>.</p><p><u>Cytochrome P450</u></p><p>Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolized by this enzyme (e.g. theophylline, clozapine,olanzapine ropinirole, tizanidine, duloxetine, agomelatine). Therefore, patients taking these substances concomitantly with ciprofloxacin should be monitored closely for clinical signs of overdose, and determination of serum</p><p>concentrations (e.g. of theophylline) may be necessary (see section 4.5). Co‐administration of ciprofloxacin and tizanidine is contra‐indicated.</p><p><u>Methotrexate</u></p><p>The concomitant use of ciprofloxacin with methotrexate is not recommended (see section 4.5).</p><p><u>Interaction with tests</u></p><p>The <em>in‐vitro </em>activity of ciprofloxacin against <em>Mycobacterium tuberculosis </em>might give false negative bacteriological test results in specimens from patients currently taking ciprofloxacin.</p><p><u>Injection Site Reaction</u></p><p>Local intravenous site reactions have been reported with the intravenous administration of ciprofloxacin. These reactions are more frequent if the infusion time is 30 minutes or less. These may appear as local skin reactions which resolve rapidly upon completion of the infusion. Subsequent intravenous administration is not contraindicated unless the reactions recur or worsen.</p><p><u>NaCl Load</u></p><p>In patients for whom sodium intake is of medical concern (patients with congestive heart failure, renal failure, nephrotic syndrome, etc.), the additional sodium load should be taken into account (for sodium chloride content, see section 2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effects of other products on ciprofloxacin:</u></p><p><em><u>Drugs known to prolong QT interval</u></em></p><p>Ciprofloxacin, like other fluoroquinolones, should be used with caution in patients receiving drugs</p><p>known to prolong QT interval (e.g. Class IA and III anti‐arrhythmics, tricyclic antidepressants, macrolides,</p><p>antipsychotics) (see section 4.4).</p><p><em><u>Probenecid</u></em></p><p>Probenecid interferes with renal secretion of ciprofloxacin. Co‐administration of probenecid and</p><p>ciprofloxacin increases ciprofloxacin serum concentrations.</p><p><u>Effects of ciprofloxacin on other medicinal products:</u></p><p><em><u>Tizanidine</u></em></p><p>Tizanidine must not be administered together with ciprofloxacin (see section 4.3). In a clinical study with</p><p>healthy subjects, there was an increase in serum tizanidine concentration (C max increase: 7‐fold, range: 4</p><p>to 21‐fold; AUC increase: 10‐fold, range: 6 to 24‐fold) when given concomitantly with ciprofloxacin.</p><p>Increased serum tizanidine concentration is associated with a potentiated hypotensive and sedative effect.</p><p><em><u>Methotrexate</u></em></p><p>Renal tubular transport of methotrexate may be inhibited by concomitant administration of</p><p>ciprofloxacin, potentially leading to increased plasma levels of methotrexate and increased risk of</p><p>methotrexate‐associated toxic reactions. The concomitant use is not recommended (see section 4.4).</p><p><em><u>Theophylline</u></em></p><p>Concurrent administration of ciprofloxacin and theophylline can cause an undesirable increase in serum</p><p>theophylline concentration. This can lead to theophylline‐induced side effects that may rarely be life</p><p>threatening or fatal. During the combination, serum theophylline concentrations should be checked and</p><p>the theophylline dose reduced as necessary (see section 4.4).</p><p><em><u>Other xanthine derivatives</u></em></p><p>On concurrent administration of ciprofloxacin and caffeine or pentoxifylline (oxpentifylline), raised</p><p>serum concentrations of these xanthine derivatives were reported.</p><p><em><u>Phenytoin</u></em></p><p>Simultaneous administration of ciprofloxacin and phenytoin may result in increased or reduced serum</p><p>levels of phenytoin such that monitoring of drug levels is recommended.</p><p><em><u>Cyclosporine</u></em></p><p>A transient rise in the concentration of serum creatinine was observed when ciprofloxacin and</p><p>cyclosporin containing medicinal products were administered simultaneously. Therefore, it is frequently</p><p>(twice a week) necessary to control the serum creatinine concentrations in these patients.</p><p><em><u>Vitamin K antagonists</u></em></p><p>Simultaneous administration of ciprofloxacin with a vitamin K antagonist may augment its anticoagulant</p><p>effects. The risk may vary with the underlying infection, age and general status of the patient</p><p>so that the contribution of ciprofloxacin to the increase in INR (international normalized ratio) is difficult</p><p>to assess. The INR should be monitored frequently during and shortly after co‐administration of</p><p>ciprofloxacin with a vitamin K antagonist (e.g., warfarin, acenocoumarol, phenprocoumon, or</p><p>fluindione).</p><p><em><u>Duloxetine</u></em></p><p>In clinical studies, it was demonstrated that concomitant use of duloxetine with strong inhibitors of the</p><p>CYP450 1A2 isozyme such as fluvoxamine, may result in an increase of AUC and C max of duloxetine.</p><p>Although no clinical data are available on a possible interaction with ciprofloxacin, similar effects can be</p><p>expected upon concomitant administration (see section 4.4).</p><p><em><u>Ropinirole</u></em></p><p>It was shown in a clinical study that concomitant use of ropinirole with ciprofloxacin, a moderate</p><p>inhibitor of the CYP450 1A2 isozyme, results in an increase of C max and AUC of ropinirole by 60% and</p><p>84%, respectively. Monitoring of ropinirole‐related side effects and dose adjustment as appropriate is</p><p>recommended during and shortly after co‐administration with ciprofloxacin (see section 4.4).</p><p><em><u>Lidocaine</u></em></p><p>It was demonstrated in healthy subjects that concomitant use of lidocaine containing medicinal</p><p>products with ciprofloxacin, a moderate inhibitor of CYP450 1A2 isozyme, reduces clearance of</p><p>intravenous lidocaine by 22%. Although lidocaine treatment was well tolerated, a possible interaction</p><p>with ciprofloxacin associated with side effects may occur upon concomitant administration.</p><p><em><u>Clozapine</u></em></p><p>Following concomitant administration of 250 mg ciprofloxacin with clozapine for 7 days, serum</p><p>concentrations of clozapine and N‐desmethylclozapine were increased by 29% and 31%, respectively.</p><p>Clinical surveillance and appropriate adjustment of clozapine dosage during and shortly after coadministration</p><p>with ciprofloxacin are advised (see section 4.4).</p><p><em><u>Sildenafil</u></em></p><p>C max and AUC of sildenafil were increased approximately twofold in healthy subjects after an oral dose</p><p>of 50 mg given concomitantly with 500 mg ciprofloxacin. Therefore, caution should be used prescribing</p><p>ciprofloxacin concomitantly with sildenafil taking into consideration the risks and the benefits.</p><p><em><u>Agomelatine</u></em></p><p>In clinical studies, it was demonstrated that fluvoxamine, as a strong inhibitor of the CYP450 1A2</p><p>isoenzyme, markedly inhibits the metabolism of agomelatine resulting in a 60‐fold increase of</p><p>agomelatine exposure. Although no clinical data are available for a possible interaction with</p><p>ciprofloxacin, a moderate inhibitor of CYP450 1A2, similar effects can be expected upon concomitant</p><p>administration (see &#39;Cytochrome P450&#39; in section 4.4).</p><p><em><u>Zolpidem</u></em></p><p>Co‐administration of ciprofloxacin may increase blood levels of zolpidem, concurrent use is not</p><p>recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>The data that are available on administration of ciprofloxacin to pregnant women indicates no malformative or feto/neonatal toxicity of ciprofloxacin. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. In juvenile and prenatal animals exposed to quinolones, effects on immature cartilage have been observed, thus, it cannot be excluded that the drug could cause damage to articular cartilage in the human immature organism / fetus (see section 5.3).</p><p>As a precautionary measure, it is preferable to avoid the use of ciprofloxacin during pregnancy.</p><p><u>Breast-feeding</u></p><p>Ciprofloxacin is excreted in breast milk. Due to the potential risk of articular damage, ciprofloxacin should not be used during breast-feeding</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to its neurological effects, ciprofloxacin may affect reaction time. Thus, the ability to drive or to operate machinery may be impaired.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Like all drug products, <strong>CIFOGRU </strong>&reg; can have side effects which need not affect everybody. However, the following incidence rating is used to evaluate the frequency of side effects:</p><p>&bull; <strong>Frequent:</strong> fewer than 1 in 10 but more than 1 in 100 treated patients</p><p>&bull; <strong>Uncommon: </strong>fewer than 1 in 100 but more than 1 in 1,000 treated patients</p><p>&bull; <strong>Rare:</strong> fewer than 1 in 1,000 but more than 1 in 10,000 treated patients</p><p>&bull; <strong>Very rare:</strong> fewer than 1 in 10,000 treated patients, including isolated cases</p><p><strong>Infections and infestations</strong></p><p>Uncommon: Mycotic super infections</p><p><strong>Blood and lymphatic system disorder:</strong></p><p>Uncommon: Increased numbers of certain white blood cells (eosinophilia).</p><p>Rare: Leukopenia, Anemia, Neutropenia, Leukocytosis, thrombocythemia and Thrombocytopenia</p><p>Very rare: Hemolytic anemia Agranulocytosis, Pancytopenia (life-threatening), and Bone marrow depression (life threatening).</p><p><strong>Immune system disorders</strong></p><p>Rare: Allergic reaction, swelling as a result of an allergic reaction (allergic Edema / angioedema)</p><p>Very rare: Hypersensitivity reaction (anaphylactic reaction), difficult breathing ranging up to lifethreatening shock (anaphylactic shock) (see section 4.4), and serum disease‐like reaction.</p><p><strong>Metabolism and nutrition disorders</strong></p><p>Uncommon: Anorexia.</p><p>Rare: Increased blood glucose (hyperglycemia) and Hypoglycemia.</p><p><strong>Psychiatric Disorders:</strong></p><p>Uncommon: Psychomotor hyperactivity/ agitation</p><p>Rare: Confusion and disorientation, anxiety reaction, abnormal dreams, depression, hallucinations.</p><p>Very rare: Psychotic reactions (potentially culminating in suicidal ideations/ thoughts or suicide attempts and completed suicide) (see section 4.4)</p><p>Frequency not known: Mania, incl. hypomania</p><p><strong>Nervous system disorders</strong></p><p>Uncommon: Headache, dizziness, sleep disorders, taste disorders.</p><p>Rare: Par‐ and Dysesthesia, Hypoesthesia, Tremor, Seizures (including status epilepticus see section 4.4) and Vertigo</p><p>Very rare: Migraine, Disturbed coordination, Gait disturbance, Olfactory nerve disorders</p><p><strong>Intracranial hypertension and pseudotumor cerebri.</strong></p><p>Frequency not known: Peripheral neuropathy and polyneur-opathy (see section 4.4)</p><p><strong>Eye disorder:</strong></p><p>Rare: Visual disturbances (including blurred and double vision)</p><p>Very rare: Visual color distortions</p><p><strong>Ear Labyrinth Disorders:</strong></p><p>Rare: Tinnitus, transient hearing disorders (e.g. ranging from difficulty hearing to loss of hearing)</p><p><strong>Cardiac Disorders:</strong></p><p>Rare: Tachycardia</p><p>Frequency not known: Ventricular arrhythmia, torsades de pointes (reported predominantly in patients with risk factors for QT prolongation), ECG QT prolonged (see sections 4.4 and 4.9)</p><p><strong>Vascular disorders:</strong></p><p>Rare: Vasodilatation, low blood pressure, Syncope.</p><p>Very rare: Inflammatory changes to the blood vessels, associated with skin symptoms (vasculitis).</p><p>Respiratory Thoracic and Mediastinal Disorders:</p><p>Rare: Difficult breathing (dyspnoea), including asthmatic conditions.</p><p><strong>Gastrointestinal disorders</strong></p><p>Frequent: Nausea, diarrhea</p><p>Uncommon: Vomiting, impaired digestion, stomach and abdominal pain, flatulence</p><p>Rare: Antibiotic associated colitis (very rarely with possible fatal outcome) (see section 4.4)</p><p>Very rare: Pancreatitis.</p><p><strong>Hepatobiliary disorders</strong></p><p>Uncommon: Increased level of certain liver enzymes in blood (transaminase), increased blood level of the bile pigment bilirubin (including hyperbilirubinemia),</p><p>Rare: Hepatic impairment, jaundice, hepatitis (non‐infective).</p><p>Very rare: Liver necrosis (ranging up to life‐threatening hepatic failure).</p><p><strong>Skin and subcutaneous tissue disorders</strong></p><p>Uncommon: Rash, pruritus, nettle rash (urticaria)</p><p>Rare: Light sensitivity with reddening of the skin (photosensitivity reactions) (see section 2)</p><p>Very rare: Punctate skin hemorrhaging (petechiae), erythema nodosum, Disc‐shaped skin reddening (erythema multifome minor) ranging up to severe skin rash taking a feverish course (Stevens Johnson syndrome), blistering, detachment of the epidermis, oral and nasal rnucosa (toxic epidermal necrolysis)</p><p>Frequency not known: Acute Generalised Exanthematous Pustulosis (AGEP), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)</p><p><strong>Musculoskeletal, connective tissue and bone disorders</strong></p><p>Uncommon: Musculoskeletal pain (e.g. extremity pain, back pain, chest pain) , Arthralgia.</p><p>Rare: Myalgia, arthritis, increased muscle tone and cramping.</p><p>Vent rare: Muscular weakness, inflammation of the tendons (tendinitis) , Torn tendons, especially the Achilles tendon, exacerbation of symptoms of myasthenia gravis (see section 4.4)</p><p><strong>Renal and urinary disorders</strong></p><p>Uncommon: Renal impairment .</p><p>Rare: Renal failure ,Haematuria ,Crystalluria (see section 4.4) ,Tubulointerstitial nephritis</p><p><strong>General disorders and administration site conditions</strong></p><p>Frequent: Local reactions at the injection site.</p><p>Uncommon: Asthenia, Fever.</p><p>Rare: Sweating (hyperhidrosis), edema.</p><p><strong>Investigations</strong></p><p>Uncommon: Increase in blood alkaline phosphatase.</p><p>Rare: Increased levels of certain enzymes (amylase).</p><p>Frequency not known: International normalized ratio increased (in patients treated with Vitamin K antagonists)</p><p><em>The following undesirable effects have a higher frequency category in the subgroups of patients receiving&nbsp;intravenous or sequential (intravenous to oral) treatment:</em></p><p><strong>Common</strong> Vomiting, Transient increase in transaminases, Rash</p><p><strong>Uncommon</strong> Thrombocytopenia, Thrombocytaemia, Confusion and disorientation, Hallucinations, Parand dysaesthesia, Seizures, Vertigo, Visual disturbances, Hearing loss, Tachycardia, Vasodilatation, Hypotension, Transient hepatic impairment, Cholestatic icterus, Renal</p><p>failure, Oedema</p><p><strong>Rare </strong>Pancytopenia, Bone marrow depression, Anaphylactic shock, Psychotic reactions, Migraine, Olfactory nerve disorders, Hearing impaired, Vasculitis, Pancreatitis, Liver necrosis, Petechiae, Tendon rupture</p><p><strong>&nbsp;</strong></p><p><strong>To reports any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><p><strong>National Pharmacovigilance and Drug Safety Centre (NPC) :</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222 , Ext 2317-2356-2340</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>An overdose of 12 g has been reported to lead to mild symptoms of toxicity. An acute overdose of 16 g has been reported to cause acute renal failure.</p><p>Symptoms in overdose consist of dizziness, tremor, headache, tiredness, seizures, hallucinations, confusion, abdominal discomfort, renal and hepatic impairment as well as crystal Luria and hematuria. Reversible renal toxicity has been reported.</p><p>Apart from routine emergency measures, ,e.g. ventricular emptying followed by medical carbon, it is recommended to monitor renal function, including urinary pH and acidify, if required, to prevent crystal Luria. Patients should be kept well hydrated. Calcium or magnesium containing antacids may theoretically reduce the absorption of ciprofloxacin in overdoses.</p><p>Only a small quantity of ciprofloxacin (&lt;10%) is eliminated by hemodialysis or peritoneal dialysis.</p><p>In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Fluoroquinolones; ATC code: J01MA02</p><p>Mechanism of action</p><p>As a fluoroquinolone antibacterial agent, the bactericidal action of ciprofloxacin results from the inhibition of both type II topoisomerase (DNA‐gyrase) and topoisomerase IV, required for bacterial DNA replication, transcription, repair and recombination.</p><p><u>Pharmacokinetic/pharm acodynamics relationship</u></p><p>Efficacy mainly depends on the relation between the maximum concentration in serum (Cmax) and the minimum inhibitory concentration (MIC) of ciprofloxacin for a bacterial pathogen and the relation between the area under the curve (AUC) and the MIC.</p><p><u>Mechanism of resistance</u></p><p>In‐vitro resistance to ciprofloxacin can be acquired through a stepwise process by target site mutations in both DNA gyrase and topoisomerase IV. The degree of cross‐resistance between ciprofloxacin and other fluoroquinolones that results is variable. Single mutations may not result in clinical resistance, but multiple mutations generally result in clinical resistance to many or all active substances within the class.</p><p>Impermeability and/or active substance efflux pump mechanisms of resistance may have a variable effect on susceptibility to fluoroquinolones, which depends on the physiochemical properties of the various active substances within the class and the affinity of transport systems for each active substance. All in‐vitro mechanisms of resistance are commonly observed in clinical isolates. Resistance</p><p>mechanisms that inactivate other antibiotics such as permeation barriers (common in Pseudomonas aeruginosa) and efflux mechanisms may affect susceptibility to ciprofloxacin. Plasmid‐mediated resistance encoded by qnr‐genes has been reported.</p><p><u>Spectrum of antibacterial activity</u></p><p>Breakpoints separate susceptible strains from strains with intermediate susceptibility and the latter from resistant strains:</p><p>E UCAST Recommendations</p><p>&nbsp;</p><p>((Table))</p><p>Staphylococcus spp. ‐ breakpoints for ciprofloxacin relate to high dose therapy.</p><p>* Non‐species‐related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for species that have not been given a species‐specific breakpoint and not for those species where susceptibility testing is not recommended.</p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><p>Groupings of relevant species according to ciprofloxacin susceptibility (for Streptococcus species see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Absorption</u></strong></p><p>Following an intravenous infusion of ciprofloxacin, the mean maximum serum concentrations were</p><p>achieved at the end of infusion. Pharmacokinetics of ciprofloxacin were linear over the dose range up</p><p>to 400 mg administered intravenously.</p><p>Comparison of the pharmacokinetic parameters for a twice a day and three times a day intravenous</p><p>dose regimen indicated no evidence of drug accumulation for ciprofloxacin and its metabolites.</p><p>A 60‐minute intravenous infusion of 200 mg ciprofloxacin or the oral administration of 250 mg</p><p>ciprofloxacin, both given every 12 hours, produced an equivalent area under the serum concentration</p><p>time curve (AUC).</p><p>A 60‐minute intravenous infusion of 400 mg ciprofloxacin every 12 hours was bioequivalent to a 500</p><p>mg oral dose every 12 hours with regard to AUC.</p><p>The 400 mg intravenous dose administered over 60 minutes every 12 hours resulted in a Cmax similar</p><p>to that observed with a 750 mg oral dose.</p><p>A 60‐minute infusion of 400 mg ciprofloxacin every 8 hours is equivalent with respect to AUC to 750</p><p>mg oral regimen given every 12 hours.</p><p><strong><u>Distribution</u></strong></p><p>Protein binding of ciprofloxacin is low (20‐30%). Ciprofloxacin is present in plasma largely in a nonionised</p><p>form and has a large steady state distribution volume of 2‐3 L/kg body weight. Ciprofloxacin</p><p>reaches high concentrations in a variety of tissues such as lung (epithelial fluid, alveolar macrophages,</p><p>biopsy tissue), sinuses, inflamed lesions (cantharides blister fluid), and the urogenital tract (urine,</p><p>prostate, endometrium) where total concentrations exceeding those of plasma concentrations are</p><p>reached.</p><p><strong><u>Biotransformation</u></strong></p><p>Low concentrations of four metabolites have been reported, which were identified as:</p><p>desethyleneciprofloxacin (M 1), sulphociprofloxacin (M 2), oxociprofloxacin (M 3) and</p><p>formylciprofloxacin (M 4). The metabolites display in‐vitroantimicrobial activity but to a lower degree</p><p>than the parent compound.</p><p>Ciprofloxacin is known to be a moderate inhibitor of the CYP 450 1A2 iso‐enzymes.</p><p><strong><u>Elimination</u></strong></p><p>Ciprofloxacin is largely excreted unchanged both renally and, to a smaller extent,</p><p>&nbsp;</p><p>((Table))</p><p>&nbsp;</p><p>Renal clearance is between 180‐300 mL/kg/h and the total body clearance is between 480‐600 mL/kg/h. Ciprofloxacin undergoes both glomerular filtration and tubular secretion. Severely impaired renal function leads to increased half‐lives of ciprofloxacin of up to 12 h.</p><p>Non‐renal clearance of ciprofloxacin is mainly due to active trans‐intestinal secretion and metabolism. 1% of the dose is excreted via the biliary route. Ciprofloxacin is present in the bile in high concentrations.</p><p><u>Paediatric patients</u></p><p>The pharmacokinetic data in paediatric patients are limited.</p><p>In a study in children C max and AUC were not age‐dependent (above one year of age). No notable increase in C max and AUC upon multiple dosing (10 mg/kg three times daily) was observed.</p><p>In 10 children with severe sepsis C max was 6.1 mg/L (range 4.6 ‐8.3 mg/L) after a 1‐hour intravenous infusion of 10 mg/kg in children aged less than 1 year compared to 7.2 mg/L (range 4.7‐11.8 mg/L) for children between 1 and 5 years of age. The AUC values were 17.4 mg*h/L (range 11.8‐32.0 mg*h/L) and 16.5 mg*h/L (range 11.0‐23.8 mg*h/L) in the respective age groups.</p><p>These values are within the range reported for adults at therapeutic doses. Based on population pharmacokinetic analysis of paediatric patients with various infections, the predicted mean half‐life in children is approx. 4‐5 hours and the bioavailability of the oral suspension ranges from 50 to 80%.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non‐clinical data reveal no special hazards for humans based on conventional studies of single dose toxicity, repeated dose toxicity, carcinogenic potential, or toxicity to reproduction.</p><p>Like a number of other quinolones, ciprofloxacin is phototoxic in animals at clinically relevant exposure Levels. Data on photomutagenicity/ photocarcinogenicity show a weak photomutagenic orPhototumorigenic effect of ciprofloxacin in‐vitroand in animal experiments. This effect was comparable to that of other gyrase inhibitors.</p><p><u>Articular tolerability</u></p><p>As reported for other gyrase inhibitors, ciprofloxacin causes damage to the large weight‐bearing joints in immature animals. The extent of the cartilage damage varies according to age, species and dose; the damage can be reduced by taking the weight off the joints. Studies with mature animals (rat, dog) revealed no evidence of cartilage lesions. In a study in young beagle dogs, ciprofloxacin caused severe</p><p>articular changes at therapeutic doses after two weeks of treatment, which were still observed after 5 months.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium Chloride, Hydrochloric Acid, Lactic acid 88%, Sodium Hydroxide and Water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ciprofloxacin solution for infusion should be administered without mixing with any other substances or infusion fluids.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C, protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Polyolefin Bags 300ml with Plug for bag</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The ciprofloxacin infusion solution is compatible with Ringer solution, Ringer lactate solution, 5 % and 10 % glucose solutions, when ciprofloxacin infusion solutions are mixed with compatible infusion solutions, for microbial reasons and light sensitivity these solutions must be administered shortly after admixture.</p><p>As the infusion solution is sensitive to light, only remove the bottles from the folding box for use. In daylight, the full efficacy of the solution is guaranteed over a period of 3 days.</p><p>For single use only.</p><p>At cool temperatures precipitation may occur, which will re‐dissolve at room temperature (15&deg;C &ndash; 25&deg;C).</p><p>The solution should be visually inspected for particulate matter and discoloration prior to administration. Only clear and colourless or slightly yellow solution should be used.</p><p>Any unused solution and the bags should be adequately disposed of, in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma Saudi 
 Riyadh – kingdom of Saudi Arabia.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aug-19
SPC-037-00
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>